{"analyses":[{"ciLowerLimit":"0.41","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.70","estimateComment":"A hazard ratio of \\<1 favoured olaparib.","groupDescription":"Analysis of olaparib 200 or 400 (n=64) versus liposomal doxorubicin (n=33).","groupIds":["OG000","OG001","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.5781","pValueComment":"2-sided p-value","paramType":"Hazard Ratio (HR)","paramValue":"0.82","statisticalComment":"Analysis was performed using a Cox proportional hazards model with factors for treatment, BRCA status and platinum sensitivity.","statisticalMethod":"Regression, Cox"},{"ciLowerLimit":"0.27","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.55","estimateComment":"A hazard ratio of \\<1 favoured olaparib.","groupDescription":"Analysis of olaparib 200 (n=32) versus liposomal doxorubicin (n=33).","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.3417","pValueComment":"2-sided p-value","paramType":"Hazard Ratio (HR)","paramValue":"0.66","statisticalComment":"Analysis was performed using a Cox proportional hazards model with factors for treatment, BRCA status and platinum sensitivity.","statisticalMethod":"Regression, Cox"},{"ciLowerLimit":"0.44","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"2.27","estimateComment":"A hazard ratio of \\<1 favoured olaparib.","groupDescription":"Analysis of olaparib 400 (n=32) versus liposomal doxorubicin (n=33).","groupIds":["OG001","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.9877","pValueComment":"2-sided p-value","paramType":"Hazard Ratio (HR)","paramValue":"1.01","statisticalComment":"Analysis was performed using a Cox proportional hazards model with factors for treatment, BRCA status and platinum sensitivity.","statisticalMethod":"Regression, Cox"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"13"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"33"}],"units":"Participants"}],"description":"OS was defined as time from randomisation to date of death from any cause. Patients who had not died at time of analysis were censored at last date they were known to be alive. Median OS was not calculable for olaparib groups due to an insufficient number of deaths so the percentage of participants who died are shown along with 95% confidence intervals","groups":[{"description":"Olaparib (AZD2281) 200 mg oral capsules twice daily","id":"OG000","title":"Olaparib 200 mg bd"},{"description":"Olaparib (AZD2281) 400 mg oral capsules twice daily","id":"OG001","title":"Olaparib 400 mg bd"},{"description":"Liposomal doxorubicin 50 mg/m2 intravenously every 4 weeks","id":"OG002","title":"Liposomal Doxorubicin"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"At the time of the cut-off for the final analysis of overall survival (30 April 2010)","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Participants"}